Cannabinoids – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 28 Jun 2023 18:33:28 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 FloraWorks Announces Scientific Breakthrough in Natural Sleep Aids: First-Ever Double-Blind, Randomized, Placebo-Controlled Clinical Trial Discovers CBN Effective for Sleep https://mjshareholders.com/floraworks-announces-scientific-breakthrough-in-natural-sleep-aids-first-ever-double-blind-randomized-placebo-controlled-clinical-trial-discovers-cbn-effective-for-sleep/ Wed, 28 Jun 2023 18:33:28 +0000 https://cannabisfn.com/?p=2973835

Ryan Allway

June 28th, 2023

News, Top News, Top Story


Independently Conducted Trial by Radicle Science Finds Florworks’s Flagship TruCBN; Showed a Significant Improvement in Sleep When Compared to Placebo

Portland, Oregon–(Newsfile Corp. – June 28, 2023) – A landmark study led by FloraWorks Holdings Inc. (“FloraWorks” or “Company”), a leading cannabinoid therapeutics company, announced the results of the first-ever double-blind, randomized, placebo-controlled trial that analyzed the effects of its flagship product, TruCBN™ – a pure form of Cannabinol (“CBN”) and one of more than 100 known cannabinoids found in the cannabis plant – on sleep.

Independently conducted by clinical-research company, Radicle Science, the groundbreaking research compared the effects of TruCBN™ against melatonin and a placebo, among more than 1,000 participants across the U.S. Each participant received one of three different doses: FloraWorks’ TruCBN™, melatonin or a placebo with the trial specifically finding that:

  • The group taking 50 mg of TruCBN™ showed a significant improvement in sleep compared to placebo, and most of the group experienced a clinically important improvement.
  • The group taking 4 mg melatonin also showed a significant improvement in sleep compared to placebo.
  • The group taking 50 mg of TruCBN™ had slightly better sleep improvements compared to 4 mg of melatonin.
  • The groups taking 25 mg and 100 mg of TruCBN™ had marginally significantly better sleep improvements compared to placebo.
  • 50 mg of TruCBN™ delivered better sleep outcomes than 25 mg or 100 mg, which is the first clinical trial data to suggest TruCBN™ may have a U-shaped dose-response curve for sleep.
  • All side effects were mild or moderate. There were no significant differences in the frequency of reported side effects between any dose of TruCBN™ or melatonin compared to placebo.

“Our results pave the way for developing more effective sleep solutions, ultimately improving the quality of life for millions of people who struggle with sleep disturbances,” said FloraWorks CEO and Cofounder Alleh Lindquist. “These findings bring needed clarity to the rapidly growing consumer demand for existing CBN products. Our TruCBN™ will be a new competitor in the global sleep aid market and marks a major milestone in building consumer trust and confidence in the therapeutic potential of cannabinoids.

Radicle Science Cofounder and CEO Jeff Chen, MD/MBA said, “The historical firsts encompassed in this study, especially discovering that CBN may have a U-shaped dose-response curve, have tremendous implications for formulating effective, natural sleep products for Americans. The findings especially highlight the importance of using the right dosage. For CBN, both too much (100 mg) and too little (25 mg) may have decreased effectiveness.”

Radicle Science Vice President of Research Affairs Dr. Susan Hewlings, PhD, RD explained, “It’s very promising to discover that CBN could be just as effective – and possibly better – than melatonin, considering many cannot tolerate melatonin’s side effects. This discussion is especially timely given the recent FDA scrutiny towards melatonin dosage and concerns about children consuming melatonin above recommended doses.”

Clinical findings like these from FloraWorks and Radicle Science have the potential to become major market disruptors to the legacy over-the-counter sleep aid market. Sixty percent (60%) of Americans report they get less than the recommended seven hours of sleep per night and poor sleep has become a public health concern as it is linked to many health issues, including inflammatory conditions, obesity, heart disease and overall reduced quality of life. As consumers increasingly seek natural and safe alternatives for better sleep, the introduction of a non-intoxicating hemp-derived cannabinoid solution presents an attractive option. TruCBN™ could lead to a decline in demand for traditional sleep aids as the results of this study build consumer trust and confidence in TruCBN™ as a natural alternative sleep aid.

About FloraWorks:

FloraWorks is a leading cannabinoid therapeutic development company specializing in high-quality, innovative products designed to improve health and wellness. With a focus on safety, efficacy and consumer trust, FloraWorks is dedicated to unlocking the therapeutic potential of rare and novel cannabinoids, and creating effective solutions that cater to a wide range of needs. For more information, visit www.flora-works.com.

About Radicle Science:

Radicle Science is history’s first Proof-as-a-Service company, enabling non-prescription health and wellness products to clinically prove their true effects beyond placebo. They offer non-pharmaceutical products the first easy path to generate first-of-its-kind clinical evidence across diverse conditions and populations at unprecedented affordability, speed, and scale. Radicle’s transformative approach democratizes access to clinical trials and can finally close the “proof gap” between non-prescription wellness products and pharmaceutical drugs.

For media inquiries, please contact:

Ellen Mellody
570-209-2947
floraworks@mattio.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement https://mjshareholders.com/emerald-health-therapeutics-and-skye-bioscience-announce-intended-closing-date-of-plan-of-arrangement/ Mon, 07 Nov 2022 16:46:49 +0000 https://www.cannabisfn.com/?p=2968108

Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction targeting glaucoma

VANCOUVER, BC, November 7, 2022– Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (CSE: EMH; OTCQB: EMHTF) and Skye Bioscience, Inc. (“Skye”) (OTCQB: SKYE) announced today that they intend to close the previously announced Plan of Arrangement (“Arrangement”) on or about November 10, 2022, and that they waived the condition that Skye obtain a conditional approval to list its shares on the Canadian Securities Exchange (“CSE”) prior to closing the Arrangement.

After careful consideration, each of the Company and Skye determined that closing the transaction at this time was in their mutual best interest. The closing of the Arrangement will, among other things, result in the Company’s shareholders receiving their shares of Skye under the Arrangement and will allow the Company to complete the sale of its remaining cannabis assets and create funds to be utilized in Skye’s Phase 1 clinical trial, which is expected to begin before the end of 2022. Although the conditional listing requirement has been waived, Skye has covenanted that it will use its best efforts to obtain the listing of its shares on the CSE as soon as possible. The Skye listing application was submitted to the CSE on August 31, 2022 and is currently under review.

Emerald recommends that shareholders holding their shares in registered accounts seek tax advice prior to the closing of the Arrangement with respect to the tax consequences of the Arrangement closing prior to the listing of Skye’s shares on the CSE.

CONTACT
Investor Relations
Email:[email protected]  
Phone: (858) 410-0266

FORWARD-LOOKING STATEMENTS

This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

]]>
Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future https://mjshareholders.com/wellbeing-subsidiary-kgk-science-opens-new-clinical-research-center-to-reimagine-a-healthier-future/ Mon, 26 Sep 2022 17:40:12 +0000 https://www.cannabisfn.com/?p=2963810

Ryan Allway

September 26th, 2022

News, Top News


New Clinical Facility in London, Ontario Accelerates Research and Innovation

VANCOUVER, British Columbia, September 26, 2022–(BUSINESS WIRE)–Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company“) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that its wholly owned subsidiary KGK Sciences Inc. (“KGK”) has opened their new Clinical Research Center in London, Ontario, with the aim to accelerate their clients’ research and drug development needs in the nutraceutical, cannabinoid, hemp and psychedelic space.

KGK will host a grand opening ceremony on September 29, 2022 to officially open the new, state-of-the-art clinical research facility and celebrate being a leading contract research organization for over 25 years. The Company’s clinical research center empowers KGK to provide high-quality clinical research trials and expert regulatory support for clients in the nutraceutical, cannabis, hemp and psychedelic industries.

As a premium full-service contract research organization, KGK is dedicated to providing clinical trial research that meets the highest quality standards. Led by a team of scientific research and regulatory experts, KGK combines cutting-edge clinical science with industry expertise to design clinical trial and claim substantiation strategies customized to meet the needs of our clients. Having over 150 publications, the company is continuously pushing study designs and measurement tools forward in the industry and were most recently published in Frontiers Journal speaking about the assessment and re-evaluation of clinical trial design. The full article can be found here: Breaking new frontiers: Assessment and re-evaluation of clinical trial design for nutraceuticals.

“Our new research center, located in the heart of London, Ontario will draw upon the strength and heritage of applied research and innovation and will be an ongoing opportunity for ground-breaking research in the fields of nutraceuticals, cannabinoids, hemp and psychedelics with global partners, clients and academics, striving for excellence as we have done over the past 25 years,” said Najla Guthrie, CEO of Wellbeing & KGK. “Our goal is to strengthen the fundamental research needed for global innovation and enable the creation of next-generation nutraceuticals and pharmaceuticals.”

Media interested in attending the opening should contact Natalie Dolphin (email: [email protected]; phone: 416-706-6364) by 12 p.m. ET on Thursday, September 29, 2022.

ABOUT KGK SCIENCE

Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.

ABOUT WELLBEING DIGITAL SCIENCES

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

On behalf of:
Najla Guthrie
Chief Executive Officer
WELLBEING DIGITAL SCIENCES

Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005255/en/

Contacts

For further information, please contact:
Natalie Dolphin
VP of Marketing & Investment Relations
Email: [email protected]
Twitter: @Wellbeing_IR

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Branded Legacy, Inc. Partners With Apple Rush Company, Inc. https://mjshareholders.com/branded-legacy-inc-partners-with-apple-rush-company-inc/ Thu, 22 Sep 2022 14:57:43 +0000 https://www.cannabisfn.com/?p=2963392

Ryan Allway

September 22nd, 2022

News, Top News


Company Adds New Delta-8 Tincture to Product Line

Orlando, FL , Sept. 22, 2022 (GLOBE NEWSWIRE) — Branded Legacy, Inc. (OTCQB: BLEG), a holding company focused on the commercial development of cannabinoid-infused products from CBD topicals and tinctures to edibles is pleased to announce it has partnered with Apple Rush Company, Inc., (OTC Pink: APRU), to make its Delta 8 tinctures for Spikes CBDX.

Apple Rush Company, Inc., a Texas corporation, is a company that engages in the business of developing, marketing, distributing, and selling products that promote a healthy lifestyle. Its primary focus is the food, beverage, snacks, anhydrous Hemp oil marketplace, kratom, kava, and other active ingredients. It is headquartered in Orlando, Florida.

Tony Torgerud, CEO of Apple Rush, stated “We are excited to partner with Branded Legacy on this product line. APRU has developed its own technologies in water solubility and have produced 100’s of thousand tinctures, drinks, chews, and other products.  We are excited to bring additional products to Branded Legacy and look forward to a long mutually beneficial relationship.”

Brandon Spikes, chairman of Branded Legacy, Inc., stated, “We are pleased to be working with Tony and Apple Rush Company. We had an opportunity to tour their facility in Titusville which was the deciding factor in doing business together. We look forward to building a long-lasting relationship and potentially working together on other projects as well.”

About Spikes CBDX: Spikes CBDX is a line of CBD products designed to assist athletes perform better, recover faster, and avoid injuries. The Company believes that post workout recovery, with Spikes CBDX products, can lower inflammation, aid in making your body stronger, and help recover from injuries naturally. The CBD line also targets individuals who are looking for pain relief, better sleep, faster recovery and lowering inflammation. Spikes CBDX provides tinctures, lotions, moisturizer, and cryo-gel roll-ons. To view all the Spikes CBDX products please visit: spikescbdx.com.

About Elev8 Hemp: Elev8 Hemp’s mission is simple: craft the highest-quality, organic hemp products for consumers in search of a healthier, happier lifestyle. Everyone needs to get the proper amount of healthy proteins to keep them feeling better and more energetic. We source only the best organic hemp protein powders—naturally full of powerhouse amino acids and Omegas-3, 6, and 9—so we can infuse your daily coffee and tea with an abundance of minerals, vitamins, antioxidants, and fiber. www.elev8hemp.com

About Versatile Industries: Versatile Industries, LLC is an acquisition company used to incubate companies to eventually spin off into their own public vehicles. Currently owns patent for a sports training assembly called The Quickness, a solar and water treatment company Magic 1 Promotions, LLC and Astound NMN. By supplementing NMN it helps maintain NAD+ levels, ultimately slowing the effects of aging. www.astoundnmn.com

Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company’s control.

www.brandedlegacy.com
(407) 337-0642
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Why Does Marijuana Smell Like a Skunk? https://mjshareholders.com/why-does-marijuana-smell-like-a-skunk/ Sun, 17 Jul 2022 02:45:09 +0000 https://www.thecannifornian.com/?p=21831 The cannabis plant is known—and even celebrated—for its distinctive skunky odor. You can find references to the pungent smell in marijuana strain names like Skunkberry, White Super Skunk, and Thelonious Skunk.

The post Why Does Marijuana Smell Like a Skunk? appeared first on The Cannifornian.

]]>
It wasn’t long ago that a distinct, sulfury skunk-like odor seeping through your car’s air vents likely meant one thing: a skunk. The mammal is known for its protective, foul-smelling anal spray—was nearby, possibly hit by a car on the highway. 

But over the past 10 years, 18 U.S. states have legalized the sale and use of recreational cannabis (and nearly 40 have some form of medical marijuana). So, it’s just as likely that the “skunky” odor you smell driving through certain areas is coming from a new kind of source: a legal marijuana grow.

Do People Like Their Marijuana to Smell Like a Skunk?

Yes, the cannabis plant is known—and even celebrated—for its distinctive skunky odor. You can find references to the pungent smell in marijuana strain names like Skunkberry, White Super Skunk, and Thelonious Skunk. 

And you can find references to it in lyrics by famous cannabis enthusiasts like the rap trio Cypress Hill.

“Skunk” strains are celebrated for their relaxation-inducing mellow and heavy highs, which many people believe help with mood disorders and anxiety.

But what exactly causes your weed to smell like a skunk? Well, thanks to nearly a century of federal cannabis prohibition making most studies of the plant illegal, we don’t know for sure. But experts do have some ideas—and some of those theories involve one of beer’s most essential ingredients: hops.

Photo: skodonnell via gettyimages.com

Photo: skodonnell via gettyimages.com

The Theories

Terpenes: Terpenes are a relatively new area of focus for most cannabis companies and producers. Terpenes are natural compounds found mostly in plants. They, among other things, produce smells and affect pigment and coloration. And you could say they’re universal: The same terpenes that make a lemon smell like lemon are likely the same terpenes that make your Super Lemon Haze strain smell like a lemon.

There’s a growing understanding within the world of cannabis that the old indica-sativa way of thinking about the effects of the cannabis plant is flawed at best and inaccurate at worst. Instead, “The Entourage Effect” concept is picking up steam. The concept posits that a combination of cannabinoids (CBD, CBG, CBN, THC, etc.) and terpenes are really what cause the unique smell, look, and effect of each cannabis strain.

Another intoxicant that Americans love to consume and sometimes refer to as “skunky” (though usually not in a good way) is beer. And beer is full of hops, which are genetically related to the cannabis plant, falling in the same plant family, called Cannabaceae. 

Experts frequently point to one terpene, myrcene, as having a particularly skunky smell—and it’s found in certain cannabis strains in addition to hops.

“While not all strains with myrcene smell like skunks, it’s a common trait—and one that stoners have grown to love,” explained Herbert Fuego, the columnist for “Ask a Stoner,” a feature in Denver’s Westword alt-weekly.

But a growing body of scientific evidence is pointing to a different culprit.

Thiols: Thiols are alcohol-like chemical compounds, except with a sulfur atom in place of the oxygen atom. They’re also the primary cause of a skunk’s defensive stench, according to 1980s research referenced by Discover Magazine.

A 2001 study by the University of Northern Carolina and Belgium’s University of Gent found that 3-MBT, a thiol similar to one emitted by skunks, causes beer to get that skunky persona. That particular thiol was found in the hops used to make the beer.

Thomas H. Shellhammer, a professor of fermentation science at Oregon State University, told Discover that the minute a beer is exposed to ultraviolet light—like sunlight—a chemical reaction occurs that quickly creates the sulfury thiol.

“If you walk outside with a nice yellow beer like a pilsner on a summer day, the change is happening almost immediately,” Shellhammer told Discover.

And the thiol theory got some serious backing in a recent peer-reviewed study by California-based terpene research and production company Abstrax Tech.

Using a technology called 2-Dimensional gas chromatography (or 2DGC) the researchers found “key volatile sulfur compounds (VSCs)—organic compounds containing sulfur” and thiols as the primary cause of the skunky smell in cannabis, according to a press release announcing the findings. The study says these compounds are actually similar to VSCs found in garlic.

“I have suspected for years now that we were missing something in our understanding of this plant,” study co-author and cannabis industry veteran Josh Del Rosso said in the release. “Although terpenes have been hailed as the major source of the pungent scent of cannabis, we now know that it is this new class of VSCs.”

So whether it’s terpenes, thiols, key volatile sulfur compounds or something else yet to be discovered, the age-old question of, “Why does my weed smell like a skunk?” has a growing body of science to be explored.

]]>
A Quick, 4-Step Guide to Making Cannabis Tinctures at Home https://mjshareholders.com/a-quick-4-step-guide-to-making-cannabis-tinctures-at-home/ Thu, 30 Jun 2022 10:45:01 +0000 https://www.thecannifornian.com/?p=21819 Not all tinctures are made the same. Even so, the list of base ingredients is pretty short. Here’s what you’ll need to make a basic cannabis tincture:

The post A Quick, 4-Step Guide to Making Cannabis Tinctures at Home appeared first on The Cannifornian.

]]>
Cannabis tinctures offer a quick and discreet way to consume cannabis. Tinctures are like small bottles of cannabis-infused alcohol, except they’re not designed to get you drunk. Many cannabis connoisseurs consider cannabis tinctures the “happy medium” between smoking and edibles because they’re smokeless, easy to dose, and you can make them at home. 

Tinctures vs. Traditional Edibles 

Although cannabis tinctures are an edible form of marijuana, they work a bit differently than pot brownies or THC gummies. You can feel the effects of a tincture within 15 minutes of ingestion. In contrast, traditional edibles can take an hour (or longer) to take effect. The sublingual tissue underneath your tongue gives the cannabinoids direct access to your bloodstream. With that being said, tinctures tend to lose their effect quicker than edible baked goods.

You take tinctures using an eyedropper, so they’re easy to dose, meaning you won’t be left guessing how much is too much. (This is a big plus for those who are new to cannabis or sensitive to the mind-altering effects of THC.) 

Benefits of Cannabis Tinctures 

One of the most apparent benefits of cannabis tinctures is their ease of use. Still, the benefits of tinctures go far beyond convenience. 

  • Precise dosing: Thanks to drop-by-drop dosing, you’ll never have to worry about getting “too high.” 
  • Low-calorie: If you can’t have THC-infused treats due to a medical condition or dietary restriction, tinctures offer a tremendous low-cal alternative. 
  • Discreet: Tinctures are smokeless (almost odorless) and come in small, portable bottles that you can easily fit in your pocket or purse. Just squeeze a drop or two underneath your tongue, and you’re good to go. 
  • Fast-acting: If taken sublingually, tinctures are fast-acting. You can usually feel the effects within 15-30 minutes. 
  • Long shelf life: Tinctures can stay fresh for years if kept in a cool, dark place.  
Photo: Amax Photo via gettyimages.com

Photo: Amax Photo via gettyimages.com

How to Make Cannabis Tinctures at Home 

Not all tinctures are made the same. Even so, the list of base ingredients is pretty short. Here’s what you’ll need to make a basic cannabis tincture: 

  • 1 cookie sheet (you can also use aluminum foil or a glass baking dish) 
  • 1 glass jar
  • 1 glass tincture bottle with eyedropper
  • 1 small kitchen funnel 
  • 1 strainer (you can use a coffee filter) 
  • Cannabis (about an eighth) 
  • High-proof, food-grade alcohol (Everclear should work) 

Once you’ve gathered your ingredients and supplies, making the tincture is easy. 

  • Step 1: Decarboxylate your cannabis. You can do this by breaking it up and popping it in the oven at 230 degrees Fahrenheit for 30 minutes. Note: If you’re using flower, be sure to grind it beforehand. You’ll want it to be super-fine.) 
  • Step 2: Once your cannabis cools down, place it in a glass jar. Then, add your Everclear (or whatever alcohol you choose). Be sure to submerge the cannabis completely. 
  • Step 3: Seal the jar and store it in a cool, dark place. For the best results, this mixture should sit for 21 days. If you can’t wait, shake the jar for three minutes and move on to the next step.
  • Step 4: Once the 21-day period is up, you’ll need to strain the cannabis-alcohol mixture. You can use a coffee filter and a small kitchen funnel to do this. Strain the mixture into your tincture bottle, and leave room for the eyedropper. 

Remember, not all tinctures are created equally, and there are hundreds of recipes out there to experiment with. The above steps will yield one bottle of basic cannabis tincture. 

The Bottom Line 

Cannabis tinctures are perfect for people who are new to consuming cannabis. With just a few ingredients, you can have a bottle of your own within 30 minutes to an hour. Cannabis tinctures also have a long shelf life, meaning you can make a batch and be set for years to come.

]]>
22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform https://mjshareholders.com/22nd-century-group-nasdaq-xxii-begins-integration-of-gvb-biopharma-creating-a-complete-robust-hemp-cannabis-platform/ Thu, 19 May 2022 00:00:12 +0000 https://www.cannabisfn.com/?p=2948106

Ryan Allway

May 18th, 2022

News, Top News


  • Complete Hemp/Cannabis Solution from Receptor Science and Plant Genetics to Final Ingredients and CDMO
  • Consistent, Reliable, High-Quality Cannabinoids and Cannabinoid Infused Products for Consumers
  • Acquisition Immediately Accretive; Will Double 22nd Century Revenue

BUFFALO, N.Y., May 18, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced that it has begun integration of GVB Biopharma, which it acquired on May 13, 2022. As a contract development and manufacturing organization (CDMO), GVB is a market share leader in hemp-derived active ingredients for the nutraceuticals, pharmaceutical and consumer goods industries. 22nd Century has posted a presentation, which includes an overview of GVB’s business operations, the compelling strategic benefits of the acquisition, and strengths of the combined companies, on the Investors section of its website, at xxiicentury.com.

James A. Mish, chief executive officer of 22nd Century Group, stated: “We are excited to welcome the GVB team into the 22nd Century family. Together, we believe 22nd Century now provides the most complete hemp/cannabis solution in the world, from receptor science and transformative plant genetics to finished ingredients and CDMO formulated products that meet the most exacting standards required by global consumer products and pharmaceutical companies. We can now offer complete, vertically integrated cannabinoid manufacturing technologies, creating industry leading scale and cost efficiency alongside our proprietary hemp/cannabis plants designed to bring the commercially desirable traits and stable genetics critical to realizing the full potential of this exciting market.”

GVB is widely regarded as a best-in-class operator with an estimated 15% share of the hemp derived active ingredients market. Its in-house capabilities address the hemp/cannabis value chain from biomass to ingredients to finished goods, ensuring attractive prices, quality, and traceability. GVB’s global foot print includes cGMP and NSF audited facilities. GVB operates three manufacturing facilities in Oregon and Nevada, including a 30,000 sq. ft. hemp ingredient manufacturing facility in Central Oregon, a 40,000 sq. ft. white-label, finished product manufacturing facility in Las Vegas, and an industrial-scale hemp extraction facility in Prineville, Oregon, which opened in 2022. The company has the capabilities to produce a large array of cannabinoids, including CBD Isolate, CBD Broad Spectrum Distillate, CBG Isolate, CBD Crystal Resistant Distillate, CBD THC-Free Crude, UK Compliant Broad Spectrum Distillate, CBN Isolate, CBC Isolate, CBDA isolate, and others. Its white-label contract manufacturing capabilities include tinctures, gel capsules, gummies, mints, tablets, topical and vape offerings. For a complete overview of GVB Biopharma, please visit their website at www.gvbbiopharma.com.

These capabilities add significant commercial scale to 22nd Century’s existing hemp/cannabis franchise, which focuses on plant science from genetics to commercial-scale plants ready for the field or greenhouse. The combination of GVB into 22nd Century also deepens its global footprint in geographic markets targeted for growth, including opportunities to accelerate 22nd Century’s strategy in key international markets.

22nd Century intends to capitalize on emerging trends in the expanding hemp/cannabis industry to generate significant increases in revenue. GVB expects 2022 revenue of approximately $48 million, a 58% increase year-over-year, gross margin in excess of 44% and positive cash flow. The transaction is expected to more than double 22nd Century’s revenue, be immediately accretive to adjusted EBITDA, and generate positive cash flow from the acquired assets in the near term.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, The Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021, now in a pilot marketing program in the United States. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube. Learn more about VLN® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
T: 716-300-1221
[email protected]

Darrow Associates Investor Relations
Matt Kreps
T: 214-597-8200
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK https://mjshareholders.com/mgc-pharmaceuticals-enters-partnership-with-sciensus-rare-for-distribution-of-cannabinoids-to-treat-refractory-epilepsy-dementia-and-alzheimers-in-the-eu-and-uk/ Tue, 05 Apr 2022 15:52:19 +0000 https://www.cannabisfn.com/?p=2942965

Ryan Allway

April 5th, 2022

News, Top News


LONDONApril 5, 2022 /PRNewswire/ — MGC Pharmaceuticals Ltd. (LSE: MXC, ASX: MXC, OTC:MGCLF), a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK.

The agreement is for the distribution in key European territories and the UK for CannEpil®, used to treat Drug Resistant Epilepsy, and CogniCann®, used to treat patients with Dementia and Alzheimer’s disease.

Sciensus Rare is an international pharmaceutical company based in the Netherlands, specializing in the provision of rare disease medicines through decentralised clinical trials and medical early access programs, with over 30-year of experience in providing health care services, and expanding medical access for products in Western Europe.

Under the terms of the distribution agreement, Sciensus Rare has been appointed the exclusive distributor of CannEpil® and CogniCann® in DenmarkFranceItalySpainLuxembourg, and the United Kingdom, some of the most advanced pharmaceutical markets in the world, for an initial 4-year term. After the initial 12 months of the agreement, Sciensus Rare will be subject to minimum purchase order requirements to maintain its exclusive distributor status. The Parties have agreed that MGC Pharma will continue to be responsible for seeking Market Authorization in these territories, while Sciensus Rare will be responsible for applications to Early Access Programmes and Named Patient Programmes.

Roby Zomer, Managing Director and CEO of MGC Pharma, commented:

“Sciensus Rare is an excellent pharmaceutical service company, with the experience and expertise necessary to increase clinical access for both CannEpil® and CogniCann® to those patients who are most in need.

This is another important step in widening patient access to our pharmaceutical products, and puts in place a long term plan to build the distribution networks required in Western Europe, one of the most important pharmaceutical markets in the world.”

Gareth Williams, President of Sciensus Rare, commented:

“We are extremely pleased to be working in partnership with MGC Pharmaceuticals within the exciting global medical cannabis market and look forward to supporting clinicians with access to both CannEpil® and CogniCann®.”

About CannEpil®

CannEpil® is a phytocannabinoid derived Investigational Medicinal Product designed to treat Drug Resistant Epilepsy with a high CBD, low THC formula, and was made available for distribution and prescription in Ireland in 2019 as part of the Ireland’s Medical Cannabis Access Programme. A research report prepared by Alacrita, a life sciences consulting company, suggested potential market in the agreement territories of 150,000 adults and children suffering from refractory epilepsy1.

About CogniCann®

CogniCann® is a phytocannabinoid derived Investigational Medicinal Product designed to treat patients with Dementia and Alzheimer’s disease, and is undergoing a Phase II clinical trial at the University of Notre Dame in PerthWestern Australia, which has been designed to evaluate the potential behavioural benefits of CogniCann® on patients suffering from these ailments.

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC, OTC: MGCLF) is a European based bio-pharma company developing and supplying affordable standardized phytomedicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in EuropeNorth America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – Epilepsy and Dementia – and has further products in the development pipeline.

Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimize cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility.

Recent research highlights the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
https://mgcpharma.com.au

About Sciensus Rare

Science International B.V. trading as Sciensus Rare, is the dedicated and enhanced rare disease medicines service business within the Sciensus group of companies, the largest speciality pharmacy provider in Europe, of complex medication management in a home environment.

Sciensus Rare is a speciality pharmacy focused on rare diseases, providing turnkey services for emerging and medium-sized biotech organizations, achieving market access for their products in Europe and beyond. Sciensus Rare offers five main services; decentralized clinical trials, medicines access, tailored supply chain management, patient and family support and outcome monitoring.

www.sciensusrare.com

For further information please contact:

MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer David Lim
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
[email protected] [email protected]
UK Broker – Turner Pope UK PR Advisors – Tavistock
Andy Thacker / James Pope Charles Vivian / Tim Pearson
+44 203 657 0050 +44 207 920 3150
[email protected] [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Dr AnnaRx Announces Rob Simbowe CBD Muscle and Joint Rubs https://mjshareholders.com/dr-annarx-announces-rob-simbowe-cbd-muscle-and-joint-rubs/ Wed, 30 Mar 2022 16:42:35 +0000 https://www.cannabisfn.com/?p=2942329

Ryan Allway

March 30th, 2022

News, Top News


CAPE TOWN, SA / ACCESSWIRE / March 30, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Dr. AnnaRx™ is pleased to announce the launch of its new line of CBD Muscle and Joint Rubs endorsed and promoted by MMA Pro Fighter Rob “The Black Tiger” Simbowe.

The initial line will consist of 3 variants:

1. CBD Pain-Relief Extra Strength Muscle Rub – 1200 mg

A deep penetrating, dual-action, medicated broad-spectrum CBD rub that is specially formulated to quickly absorb through the skin and muscle to provide pain relief from muscle and joint-related injuries, strains, and sprains. On contact, it provides deep cooling relief, then activates to heat for deep-penetrating, long-lasting pain alleviation.

2. CBD Warming Pre-Workout Muscle Rub – 600 mg

A medicated broad-spectrum CBD pre-workout muscle rub clinically designed to warm and prepare your muscles before your workout, helps protect against muscle and joint-related injuries, strains, and sprains.

3. CBD Cooling Post-Workout Muscle Rub – 600 mg

A medicated broad-spectrum CBD post-workout muscle rub clinically designed to soothe and cool your muscles post-workout, helps protect against muscle and joint-related injuries, strains, and sprains.

The muscle rubs are a new and exciting addition with strong brand differentiators in the category. They will be available in select major pharmacies and health store chains in South Africa first, then Zambia – Rob’s country of birth and upbringing.

“Having Rob represent the Dr. AnnaRx™ brand is a real honor for us. He has an incredible life story that is so inspiring. His deep knowledge of health, fitness, nutrition, and life skills is remarkable. He’s a true role model for the youth and anyone who aspires to do great things. We are also very excited to serve our consumers with these extraordinary three CBD products. The muscle rubs are made using the highest quality CBD from Colorado, USA, African medicinal ingredients and formulated for maximum results.” – Dr. Anna Morera Leralta – Chief Medical Officer, M2Bio Sciences.

Rob Simbowe, Director of Health and Fitness and Brand Ambassador, M2Bio Sciences added: “The meaning of life is not simply to exist, to survive, but to move ahead, to go up, to achieve, to conquer. The meaning of life differs from man to man, from day to day, and from hour to hour, and that’s why I fight not just in the ring but outside in life too – to be the best version of myself I can possibly be. I use CBD as part of my daily regimen to not let any pain stand in my way – it helps me train harder and be the best version of myself when training and competing.”

ROB SIMBOWE UPCOMING FIGHT:

Simbowe vs Dogodo
Date: 09, April 2022
Venue: EFC Performance Institute, Johannesburg, South Africa
Find out more here

IMMAF Africa Championships

Rob has recently been selected as part of the coaching staff for the IMMAF Africa Championships, his grass route connection and popularity within the Zambian sporting community allow for the perfect platform launch into the country:

MMA Zambia is the governing body for Mixed Martial Arts in Zambia, mandated by the National Sports Council of Zambia to regulate the sport in the country.

We are proud to have Rob Simbowe on the MMA Zambia board. Rob is a pioneer of the sport here; he is Zambia’s first-ever Pro MMA athlete and EFC fighter. Due to his wealth of experience, he has been selected to be part of the MMA Zambia coaching staff for the IMMAF Africa Championships taking place at the EFC Performance Institute in Johannesburg from the 28th to the 30th of April 2022.

The Dr. AnnaRx™ CBD muscle relief line endorsed by Rob is a fantastic product for athletes and recreational fitness enthusiasts alike. You can be assured that with Rob’s name associated with the brand, like Rob, it does everything it says it does and more. We look forward to our athletes using it as a strong and effective aid for recovery after training and competition,” says Benjamin Bush – MD – Ulemu Fight Academy, President – MMA Zambia.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)

Visit Website
Contact via E-mail
Follow us on Twitter
Follow us on Facebook
Follow us on YouTube
Follow us on Instagram

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Hempsana Signs Partnership with GAMA Corp to Launch New Product Offerings and Brands https://mjshareholders.com/hempsana-signs-partnership-with-gama-corp-to-launch-new-product-offerings-and-brands/ Mon, 28 Mar 2022 16:54:54 +0000 https://www.cannabisfn.com/?p=2942111

Ryan Allway

March 28th, 2022

News, Top News


TORONTO, March 28, 2022–(BUSINESS WIRE)–Hempsana Holdings Ltd. (the “Company” or “Hempsana“) a leader in the production and refinement of cannabinoids and Cannabis 2.0 products, is delighted to announce that it has entered into a contract manufacturing agreement with GAMA Corp (“GAMA“) to co-manufacture and distribute new products and well recognized brands from the United States to the Canadian and International Markets for both recreational and medicinal use.

Under the terms of the agreement, GAMA will leverage Hempsana’s EU GMP compliant facility and its full suite of product manufacturing capabilities to support the product development of the following product categories:

  • THC Diamonds
  • Infused Pre-Rolls
  • Hash
  • Edibles
  • Topicals

“We are extremely excited to partner with GAMA Corp to deliver Contract Manufacture Operation (CMO) services as we continue to expand our manufacturing capabilities into underrepresented product categories in the cannabis space. We’re especially excited about the launch of various recognized brands for the Canadian consumers and medical patients,” said Randy Ko, Chief Executive Officer of Hempsana.

Combined, Hempsana and GAMA have over 195 SKUs that are currently under review with Health Canada and will be available to be purchased by Provincial Wholesalers by the beginning of summer 2022 with additional white label service offerings for LPs and brands interested in highly innovative products not yet available in the marketplace.

About Hempsana Holdings Ltd.

The Company’s business involves the manufacturing of major and minor cannabinoid derivatives and producing cannabis extracts for use in finished products, including topical creams, vape pens and other infused consumables. Hempsana’s Health Canada Standard Processing Licensed, and EU-GMP compliant facility provides the Company access to wholesale and retail channels in Canada and internationally. Hempsana currently offers a wide range of product formats, including topicals, tinctures, salves, vape pens which can all be fortified with major and minor cannabinoids that are all manufactured and distributed by Hempsana.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian and U.S. securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. More particularly and without limitation, this press release contains forward looking statements and information concerning the business and operations of the Company. The forward-looking statements and information are based on certain key expectations and assumptions made by management, including expectations and assumptions concerning the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information. There can be no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. These risks and uncertainties, include, but are not limited to, general economic conditions and the state of the regulatory environment. Please refer to the Company’s public record on SEDAR at www.sedar.com for more details on the risks faced by the Company. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date hereof, and to not use such forward- looking information for anything other than its intended purpose. Management of the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Additional Information
For additional information regarding Hempsana, please contact:

Randy Ko
Director and Chief Executive Officer
T: (647) 255-8849
E: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>